Epigenetic modifier screen for human AML. Numerous compounds and small molecules are currently available that interfere with particular known epigenetic processes. Large-scale titration sensitivity experiments of these molecules in primary AML specimens in vitro can provide compound response signatures of each AML sample (A). Using those assays, AML subtypes may be uncovered that uniformly respond to specific epigenetic compounds (B). The molecular, epigenetic, and biological effects to these AML cells may subsequently be studied in vitro and in vivo (C). The outcomes of such experiments should lead to the translation to clinical trials in human patients (D).